Pricing
2013 healthcare spending crept upwards
January 06, 2015Centers for Medicare and Medicaid Services says it is too early to blame a sluggish economy for slow growth.
Gilead may be forced to discount hep. C pills
December 23, 2014AbbVie's deal with the PBM Express Scripts has altered the dynamic in hepatitis C price-setting, writes Bloomberg.
High deductibles, costs keep patients away
December 02, 2014More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.
World projected to spend $1T on drugs in 2018
November 20, 2014The IMS Institute for Healthcare Informatics notes that developed markets remain a key driver.
Cigna lowers price of some HIV medications
November 10, 2014The deal will cap the monthly price some patients may pay for medications such as Atripla.
Specialty prescription costs hurt across the board
October 09, 2014Solutions for how to handle specialty medication costs are lacking, but the data around them shows a need for serious problem-solving.
Nearly half of consumers wary of healthcare costs, insurer finds
October 07, 2014Cigna said found paying for medications and hospitalizations were top healthcare concerns.
Five things for pharma marketers to know: Friday, September 19
September 19, 2014Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.
DOJ eyes Ranbaxy pricing
September 17, 2014The Department of Justice is looking into Medicaid pricing.
Switzerland wants lower drug prices
September 17, 2014Switzerland is pushing Roche to lower its prices on Perjeta
Drug spend will continue to rise through 2023
September 04, 2014The numbers folks at the Centers for Medicare and Medicaid Services anticipate sluggish growth in US healthcare spend, but prescriptions look ready to take off.
Study: move more, eat less, save $500
August 25, 2014Diet and exercise can help some type-2 diabetes patients save around $500 in medical expenses every year.
Five things for pharma marketers to know: Friday, August 15
August 15, 2014UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.
Britain's NICE sidelines Kadcyla
August 11, 2014Britain's National Institute for Health and Care Excellence has followed through on its Kadcyla objections and has said Roche's breast cancer drug will remain off the National Health Services formulary because it is too expensive.
Site has doctors bid for business
August 07, 2014Medibid users auction up care in exchange for a low price.
WellPoint tests prices, patients
August 06, 2014Health insurer WellPoint found patients chose lower-priced MRIs when shown how much locations charged for the very same procedure, but the motivation is murky.
Acthar marketing drives prescriptions and anger
August 05, 2014The decades-old drug is winning prescriptions through marketing, but has a free-pass when it comes to clinical trial data.
Express Scripts drops Zohydro, brings back Advair
August 04, 2014The PBM dropped 25 more drugs from its formulary.
Lawmakers eye pricing
July 30, 2014The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.
Gilead, Merck HCV marketing battle may be on horizon
July 24, 2014Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Generics trigger wallet shock
July 09, 2014Prices for some generics are rising, thanks to limited competition.
Experiment cuts cancer costs, ups drug spend
July 09, 2014UnitedHealthcare finds drug costs more than doubled.
France ponders off-label Avastin
July 02, 2014French lawmakers have the chance to vote for off-label use of Avastin, potentially eating into the turf of higher-priced Lucentis.
Italy: Use Avastin off-label
June 12, 2014The Italian Medicines Agency is guiding patients away from Roche's costlier AMD-indicated Lucentis.
Oregon seeks HCV Rx waiver
June 12, 2014The Oregon Health Plan wants to keep hep. C medications Sovaldi and Olysio off its list of covered treatments.
China lifts some pricing restrictions
May 08, 2014Drug quality problems and shortages are behind the shift that will affect antibiotics, painkillers and vitamins.
Survey finds pharma and payers not aligned
May 07, 2014An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.
Sovaldi Rx are being filled, despite payer angst
April 21, 2014Physicians tell Leerink most of their patients are receiving the drug. Rejections tend to be over off-label use.
2013 favored specialists, specialty Rx
April 15, 2014The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.
Diabetes costliest among non-specialty Rx
April 09, 2014Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.
This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.
MMM Articles
- Novartis psoriasis drug approval could upend market
- Sandoz gets ready to make the biosimilar case with oncologists
- Guidemark Health jumpstarts rebrand, brings on big-agency grad
- MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics
- Nurse practitioner workforce has just about doubled
